Evotec SE
Evotec SE (EVO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EVO · as of Jun 9, 2026
Key Statistics
Explore Evotec SE Data
evo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 57.1%
The EVO analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $7.00, representing +149.11% upside from the current price of $2.81.
Competitors & Peers
evo competitorsEVO
ALVO
AZTA
HROW
NVCR
PCRXStock Performance
Full HistoryAbout Evotec SE
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive res…
what is evotec se · evo stock overview · evotec se company profile · who is evotec se ceo · evo NASDAQ · evotec se headquarters · evotec se business segments
About Stock Overview & Key Data
Evotec SE (EVO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Feb 5, 2004. As of the latest trading session, EVO stock price is $2.81, with a market capitalization of $998.1M. The stock has returned -32.04% over the past 12 months and -9.09% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Evotec SE stock is Buy, with an average 12-month price target of $7.00. In fiscal year 2025, Evotec SE reported revenue of $757.3M and net income of -$99.4M. For detailed data — including Evotec SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Evotec SE (EVO) stock price is $2.81. The stock is traded on NASDAQ under the ticker symbol EVO. The 52-week range is $2.31 – $4.44.